RecruitingEarly Phase 1NCT06757153

Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients

Studying Astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhongnan Hospital
Principal Investigator
Zhiqiang Li, MD
Zhongnan Hospital
Intervention
NRG-103(drug)
Enrollment
15 target
Eligibility
18 years · All sexes
Timeline
20242027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06757153 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma

← Back to all trials